Clinical Trial Update: Effect of SRT2379 on Endotoxin-Induced Inflammation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating SRT2379 for endotoxin-induced inflammation in sepsis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• SRT2379

Snippet

Sponsor: Sirtris, a GSK Company | Conditions: Sepsis | Phase 1 | Status: COMPLETED